Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2347${count})

  • Rapid Response Innovation Awards, 2011
    Fractalkine-CX3Cr1 Signaling in Models of Parkinson Disease: Quest for Novel Therapeutic Strategies

    Objective/Rationale: 
    Microglia, one of the key players in neuroinflammation, are increased in number and activated in the brains of Parkinson’s disease (PD) or pre-clinical models of PD. A recent...

  • Rapid Response Innovation Awards, 2011
    The Development of Novel Adeno-associated Virus Vectors for Intravenous Parkinson's Gene Therapy

    Objective/Rationale:
    As Parkinson disease progresses, a wide range of brain areas exhibit evidence of inflammation and degeneration, but presently no therapies exist that selectively target these...

  • Rapid Response Innovation Awards, 2011
    Developing and Characterizing Anti-Alpha-Synuclein Nanobodies from an Immune Phage Display Library

    Objective/Rationale:
    This project uses a novel approach to deal with alpha-synuclein, which accumulates abnormally in Parkinson’s disease (PD). Cutting-edge recombinant antibody technologies will...

  • Rapid Response Innovation Awards, 2011
    Ability of a Mitochondria Improver, Berberine, to Attenuate Parkinson's Disease

    Objective/Rationale: 
    Mitochondrial dysfunction is a central modification underlying the damage of dopamine neurons in Parkinson’s disease (PD). Our hypothesis is that drugs able to stabilise...

  • Rapid Response Innovation Awards, 2011
    Alpha-synuclein May Be Responsible for the Link Between Parkinson's Disease and Melanoma

    Objective/Rationale: 
    Although the association between Parkinson’s disease (PD) and melanoma has been well established, biological explanations are still lacking. PD-causing gene alpha-synuclein is...

  • MJFF Research Grant, 2011
    Identification of Nrf2 Activators Using an In Silico Modeling Platform, Followed by Evaluation of These Compounds in an Alpha-Synuclein Model of PD

    Objective/Rationale: 
    Oxidative stress has been implicated in the etiology of Parkinson’s disease (PD). Under such conditions, the transcription factor NF-E2-related factor (Nrf2) binds to antioxidant...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.